For Patients & Visitors

Doctor Details

Find a Doctor
Doctor Detail

Dr Melissa Ooi Gaik Ming

Photo of Dr Melissa Ooi Gaik Ming


  • Senior Consultant, Division of Haematology, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Senior Consultant, Department of Haematology, Ng Teng Fong General Hospital
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore





Special Interests:

Plasma cell dyscrasias, Acute leukaemia, Myelodysplasia

Find Out More:


Dr. Melissa Ooi is a specialist in general haematology and haematology-oncology and currently practices as a senior consultant at the National University Cancer Institute, Singapore. She is an Assistant Professor at the Yong Loo Lin School of Medicine, NUS.

Dr Ooi graduated from the Royal College of Surgeons in Ireland. She underwent medical and haematology training in Ireland where she obtained her postgraduate qualification. During her specialty training, she was awarded a research fellowship in the Jerome Lipper Multiple Myeloma Center in the Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. She worked under Professor Kenneth Anderson and Dr. Constantine Mitsiades in Dana Farber and with Dr. Peter O’Gorman, Professor Martin Clynes and Dr. Robert O’Connor at the National Institute of Cellular Biotechnology in Dublin City University. This collaborative research resulted in a number of peer-reviewed journal publications and presentations at international meetings. Dr. Ooi was awarded her PhD from Dublin City University in 2011. She then went on to complete her haematology specialist training and was awarded her CSCST in 2013.

Dr Ooi worked as a consultant in Dublin, Ireland before joining the National University Cancer Institute, Singapore in 2014. Since starting in Singapore, she has continued her research and received national and institutional peer-reviewed grants. She is currently the leukaemia group lead at the National University Cancer Institute, Singapore and is also heavily involved in myeloma, leukemia and myelodysplasia clinical care and research. Aside from patient care, Dr Ooi is an advocate for patient safety and patient experience. She is also involved in shaping the next generation of doctors as a lecturer of haematology in undergraduate studies and a core faculty in the postgraduate haematology programme.

Journals & Publications

  1. Yow KS, Liu X, Chean NC, Tung ML, Yan B, Christoper D, Ong KH, Ooi MG.Relationship of JAK2 (V617F) Allelic Burden with Clinico- Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms. Asian Pac J Cancer Prev 2020 Sep 1;21(9):2805-2810. PMID: 32986384
  2. Myoung ES, Neja, SA, Fidan K, Chua JYH, Chung TH, Bertin N, Tergaonkar V, Chng WJ, Ooi MG. Lymphocyte cytosolic protein1 (LCP1) is a novel TRAF3 dysregulation biomarker with potential prognostic value in multiple myeloma. Genome Instability & Disease 2020 June Doi10.1007/s42764-020-00014-x
  3. Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in Multiple Myeloma. Cells 2020 Mar 3;9(3):601 Doi:10.3390/cells9030601. PMID: 32138182
  4. Ojha S, Ooi MG. Pregnancy exposure to midostaurin in the first trimester. Ann Hematol. 2020 Jan 3. Doi: 10.1007/s00277-019-03903-8 [Epub ahead of print].
  5. Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ. Aberrant hyperediting of the myeloma transciptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood 2018 Sep 20;132(12):1304-1317.
  6. Ooi MG, de Mel S, Chng WJ. Risk Stratification in Multiple Myeloma. Curr Hematol Malig Rep. 2016 Apr;11(2):137-47 Epub Feb 16.
  7. Ooi MG, O'Connor R, Meiller J, Jakubikova J ,Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P. The Interaction of Bortezomib with Multidrug Transporters: Implications for Therapeutic Applications in Advanced Multiple Myeloma and Other Neoplasias. Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. Epub 2013 Apr 16
  8. Ong SY, de Mel S, Chen YX, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AY, Hwang WY, Phipps C, Loh SM, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. Bone marrow Transplant 2016 Mar 14 [Epub ahead of print].

Last updated on
Best viewed with Chrome 79.0, Edge 112.0, Firefox 61.0, Safari 11
National University Health System
  • National University Hospital
  • Ng Teng Fong General Hospital
  • Alexandra Hospital
  • Jurong Community Hospital
  • National University Polyclinics
  • Jurong Medical Centre
  • National University Cancer Institute, Singapore
  • National University Heart Centre, Singapore
  • National University Centre for Oral Health, Singapore
  • NUHS Diagnostics
  • NUHS Pharmacy
  • Yong Loo Lin School of Medicine
  • Faculty of Dentistry
  • Saw Swee Hock School of Public Health
Back to Top